[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 28 of about 28
1. Ellouze S, Krichen-Makni S, Trabelsi K, Ayadi L, Sellami A, Khabir A, Hammami S, Mnif H, Sellami-Boudawara T: [Granulosa-cell tumor of the ovary: report of 16 cases]. J Gynecol Obstet Biol Reprod (Paris); 2006 Dec;35(8 Pt 1):767-72
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Granulosa-cell tumor of the ovary: report of 16 cases].
  • [Transliterated title] Tumeur de la granulosa de l'ovaire: à propos de 16 cas.
  • OBJECTIVE: The aim of this work was to describe the epidemiological, pathological and clinical features of granulosa cell tumors and to study the different prognostic factors in order to determine an appropriate therapeutic attitude.
  • PATIENTS AND METHODS: We proceeded with a retrospective study of 16 cases of granulosa cell tumors of the ovary diagnosed over a period of 10 years (1994-2003).
  • These cases included one case of juvenile type and 15 adult types.
  • RESULTS: Mean patient age was 46 years for the adult type (range 20-70 years) and 35 years for the juvenile type; 19% of the patients were nulliparous, 31% were menopausals.
  • Mean tumor size was 10.5 cm with a solido-cystic aspect in 50% of cases.
  • The treatment was surgical in all cases.
  • The juvenile tumor was at stage IV at time of diagnosis and only adjuvant chemotherapy was given.
  • No relapse nor recurrence were noted for the adult type after a mean follow up of 2 years 2 months.
  • For the juvenile form, locoregional recurrence with liver metastasis developed after 9 months.
  • CONCLUSION: Granulosa cell tumor of the ovary is an uncommon neoplasm.
  • The juvenile forms are more exceptional and more aggressive.
  • A prolonged post therapeutic follow-up is necessary because of the risk of recurrences, late and exceptional for the adult form but frequent and early for the juvenile form.
  • [MeSH-major] Granulosa Cell Tumor / pathology. Granulosa Cell Tumor / surgery. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adult. Age Factors. Aged. Female. Humans. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Neoplasm Staging. Parity. Postmenopause. Pregnancy. Prognosis. Retrospective Studies. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17151531.001).
  • [ISSN] 0368-2315
  • [Journal-full-title] Journal de gynécologie, obstétrique et biologie de la reproduction
  • [ISO-abbreviation] J Gynecol Obstet Biol Reprod (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


2. Tao X, Sood AK, Deavers MT, Schmeler KM, Nick AM, Coleman RL, Milojevic L, Gershenson DM, Brown J: Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors. Gynecol Oncol; 2009 Sep;114(3):431-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors.
  • OBJECTIVE: Ovarian granulosa cell tumors tend to respond poorly to chemotherapy.
  • We examined the clinical efficacy of bevacizumab with or without concurrent chemotherapy and evaluated the angiogenic characteristics of these patients' tumors.
  • METHODS: We conducted a retrospective review of all patients seen at our institution from February 2004 to October 2008 who received bevacizumab for ovarian sex cord-stromal tumors.
  • We performed immunohistochemical staining for vascular endothelial growth factor (VEGF) and CD31 when tissue was available; microvessel density was measured based on CD31 staining.
  • RESULTS: We identified 8 patients who were treated with bevacizumab; 7 had adult granulosa cell tumors and one had a juvenile granulosa cell tumor.
  • All patients had recurrent disease and had been previously treated with cytotoxic chemotherapy (median 3.5 regimens; range, 1-6).
  • One patient had a complete clinical response to bevacizumab therapy, 2 patients had a partial response, 2 patients had stable disease, and 3 patients' disease progressed, yielding a response rate of 38% and a clinical benefit rate of 63%.
  • CONCLUSIONS: Anti-VEGF therapy is highly effective in patients with granulosa cell tumors.
  • Based on our observations, a prospective trial has been initiated using single-agent bevacizumab in patients with recurrent ovarian sex cord-stromal tumors.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Granulosa Cell Tumor / blood supply. Granulosa Cell Tumor / drug therapy. Ovarian Neoplasms / blood supply. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Humanized. Antigens, CD31 / metabolism. Bevacizumab. Female. Humans. Immunohistochemistry. Middle Aged. Neovascularization, Pathologic / drug therapy. Neovascularization, Pathologic / metabolism. Retrospective Studies. Vascular Endothelial Growth Factor A / metabolism. Young Adult

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19524286.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / T32 CA101642
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antigens, CD31; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab
  • [Other-IDs] NLM/ NIHMS645749; NLM/ PMC4263417
  •  go-up   go-down


3. Distelmaier F, Calaminus G, Harms D, Sträter R, Kordes U, Fleischhack G, Göbel U, Schneider DT: Ovarian small cell carcinoma of the hypercalcemic type in children and adolescents: a prognostically unfavorable but curable disease. Cancer; 2006 Nov 1;107(9):2298-306
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian small cell carcinoma of the hypercalcemic type in children and adolescents: a prognostically unfavorable but curable disease.
  • BACKGROUND: Ovarian small cell carcinoma of the hypercalcemic type is a rare neoplasm that is associated with a poor prognosis.
  • The objective of the current study was to investigate the clinicopathologic features of this tumor and to develop preliminary diagnostic and therapeutic guidelines.
  • METHODS: Between 1994 and 2005, 11 girls (ages 9-22 years) who were registered on the German Maligne Keimzelltumoren studies and the Kiel Pediatric Tumor Registry were analyzed.
  • Prior to histopathologic review, 8 patients had been misdiagnosed with either germ cell tumor or juvenile granulosa cell tumor.
  • After resection, 4 patients were followed without additional therapy, and all 4 patients developed recurrent disease after 3 to 11 months.
  • Seven patients received adjuvant chemotherapy during first-line treatment.
  • During first-line treatment, high-dose chemotherapy was received by 4 patients who achieved a complete response (CR) after conventional chemotherapy.
  • All 4 of those patients remained in CR for 7 to 73 months, whereas the other 3 patients developed recurrent disease.
  • Salvage treatment after recurrence or tumor progression consisted of surgery and chemotherapy.
  • One patient received high-dose chemotherapy in 2nd CR and remained in 2nd CR.
  • CONCLUSIONS: Patients with ovarian small cell carcinoma of the hypercalcemic type require multiagent chemotherapy during first-line treatment.
  • High-dose chemotherapy may be used to consolidate the therapeutic success.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Hypercalcemia / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Child. Combined Modality Therapy. Diagnosis, Differential. Disease-Free Survival. Female. Humans. Neoplasm Staging. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian small cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 American Cancer Society.
  • (PMID = 16998935.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Guo H, Keefe KA, Kohler MF, Chan JK: Juvenile granulosa cell tumor of the ovary associated with tuberous sclerosis. Gynecol Oncol; 2006 Jul;102(1):118-20
MedlinePlus Health Information. consumer health - Tuberous Sclerosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Juvenile granulosa cell tumor of the ovary associated with tuberous sclerosis.
  • BACKGROUND: Tuberous sclerosis is a neurocutaneous syndrome characterized by benign tumors that can affect many organs.
  • Juvenile granulosa cell tumors of the ovary are rare neoplasms that typically occur in the first three decades of life and have excellent prognosis for early-staged disease.
  • CASE REPORT: We report the first case of an 8-year-old white female with tuberous sclerosis and juvenile granulosa cell tumor of the ovary.
  • She presented with a 20 x 22 cm pelvic mass and received a right salpingo-oophorectomy.
  • Three months later, she recurred and underwent a left salpingo-oophorectomy, lymphadenectomy, and omentectomy followed by four cycles of Bleomycin, Etoposide, and Cisplatin chemotherapy.
  • CONCLUSION: Treatment options and a review of the literature pertaining to juvenile ovarian granulosa cell tumors and tuberous sclerosis are discussed.
  • [MeSH-major] Granulosa Cell Tumor / complications. Ovarian Neoplasms / complications. Tuberous Sclerosis / complications

  • Genetic Alliance. consumer health - Tuberous sclerosis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16516278.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Powell JL, Connor GP, Henderson GS: Management of recurrent juvenile granulosa cell tumor of the ovary. Gynecol Oncol; 2001 Apr;81(1):113-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of recurrent juvenile granulosa cell tumor of the ovary.
  • BACKGROUND: Juvenile granulosa cell tumors of the ovary are a rare form of neoplasm that makes up less than 5% of ovarian tumors in childhood and adolescence.
  • About 90% are diagnosed in stage I with a favorable prognosis.
  • CASE: A patient was initially diagnosed at age 17 with FIGO stage IIIC disease and treated with a right salpingo-oophorectomy, debulking, and staging followed by six cycles of carboplatin and etoposide chemotherapy.
  • Tumor recurrence in the liver and adjacent to the spleen occurred 13 months after completion of primary therapy.
  • Aggressive surgical removal of tumor followed by six cycles of bleomycin and taxol as salvage chemotherapy resulted in 44 months of disease-free survival.
  • Exploration revealed no evidence of tumor.
  • CONCLUSION: This is the second case report of a patient with advanced juvenile granulosa cell tumor to become pregnant after apparently successful chemotherapy.
  • These results are encouraging, but the best treatment for extensive and recurrent disease has yet to be determined.
  • [MeSH-major] Granulosa Cell Tumor / drug therapy. Granulosa Cell Tumor / surgery. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / surgery. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Academic Press.
  • (PMID = 11277661.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Piura B, Wiznitzer A, Shaco-Levy R: Juvenile granulosa cell tumor of the ovary associated with hypercalcemia. Arch Gynecol Obstet; 2008 Mar;277(3):257-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Juvenile granulosa cell tumor of the ovary associated with hypercalcemia.
  • INTRODUCTION: Juvenile granulosa cell tumors (JGCTs) are rare ovarian neoplasms that typically occur in children and young women.
  • While most JGCTs are diagnosed in Stage IA and can be cured by unilateral oophorectomy alone, the remainders are diagnosed in more advanced stages and may exhibit aggressive behavior despite surgery and chemotherapy.
  • Paraneoplastic hypercalcemia occurs in 5% of ovarian malignancies with small cell and clear cell carcinoma being the commonest ovarian tumors associated with hypercalcemia.
  • CASE REPORT: A 25-year-old married childless woman presented with a unilateral ovarian mass associated with profound hypercalcemia and suppressed serum parathyroid hormone-intact (PTH-i) level.
  • After rectifying the hypercalcemia with saline hydration, furosemide, and anti-hypercalcemic drugs, the patient underwent unilateral salpingo-oophorectomy that demonstrated Stage IC ovarian JGCT.
  • The patient received adjuvant chemotherapy with three courses of BEP (bleomycin, etoposide and cisplatin) and to date, ten months after surgery, she is disease-free, eucalcemic, and menstruating normally.
  • Since serum PTH-i level was suppressed and the hypercalcemia did not recur after resection of the tumor, it is concluded that the hypercalcemia was caused by parathyroid hormone-related protein (PTH-rP) produced by the tumor.
  • It seems that unilateral salpingo-oophorectomy followed by BEP chemotherapy is an appropriate treatment for unilateral Stage IC ovarian JGCT in women desiring to preserve ovarian function and childbearing capacity.
  • [MeSH-major] Granulosa Cell Tumor / diagnosis. Hypercalcemia / etiology. Ovarian Neoplasms / diagnosis. Paraneoplastic Syndromes / diagnosis
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Female. Humans. Parathyroid Hormone / blood

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17849133.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Parathyroid Hormone
  •  go-up   go-down


7. Peng P, Shen K, Lang J, Cui Q, Wu M: Clinical analysis of 4 cases of juvenile granulosa cell tumor of the ovary. Zhonghua Fu Chan Ke Za Zhi; 2002 Jul;37(7):402-4
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical analysis of 4 cases of juvenile granulosa cell tumor of the ovary.
  • OBJECTIVE: To review the diagnosis, treatment and prognosis of juvenile granulosa cell tumor of the ovary (JGCT).
  • All 4 patients were at stage I and treated with surgery and combined chemotherapy.
  • Cytoreductive surgery is the treatment of choice and combination chemotherapy may be helpful to improve the prognosis of JGCT.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12411036.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


8. Frausto SD, Geisler JP, Fletcher MS, Sood AK: Late recurrence of juvenile granulosa cell tumor of the ovary. Am J Obstet Gynecol; 2004 Jul;191(1):366-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late recurrence of juvenile granulosa cell tumor of the ovary.
  • Juvenile granulosa cell tumor (JGCT) of the ovary, if diagnosed at an early stage, has a favorable prognosis.
  • The patient presented here was treated with a left oophorectomy after initial presentation.
  • Tumor recurrence in the left adnexa, diagnosed 48 months later, was treated with cytoreductive surgery followed by chemotherapy; she remains disease free 19 months after this recurrence.
  • [MeSH-major] Granulosa Cell Tumor / therapy. Neoplasm Recurrence, Local / surgery. Ovarian Neoplasms / therapy. Pregnancy Complications, Neoplastic / therapy

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15295395.001).
  • [ISSN] 0002-9378
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Hirakawa M, Nagai Y, Yagi C, Nashiro T, Inamine M, Aoki Y: Recurrent juvenile granulosa cell tumor of the ovary managed by palliative radiotherapy. Int J Gynecol Cancer; 2008 Sep-Oct;18(5):913-5
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent juvenile granulosa cell tumor of the ovary managed by palliative radiotherapy.
  • Prognosis in the few patients with advanced-stage juvenile granulosa cell tumor (JGCT) of the ovary has traditionally been unfavorable.
  • A 37-year-old woman with recurrent JGCT received a combination of paclitaxel-carboplatin chemotherapy and then single-agent docetaxel, but her disease progressed with multiple abdominal masses and ascites.
  • We chose palliative radiation therapy to relieve her complaints.
  • She tolerated the treatment well.
  • After the completion of radiotherapy, ultrasonography showed shrinkage of the tumor, and the ascites disappeared.
  • We should consider using radiation therapy in a palliative setting for such patients with recurrent JGCT suffering from abdominal complaints.
  • [MeSH-major] Granulosa Cell Tumor / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Palliative Care
  • [MeSH-minor] Adult. Biopsy. Female. Humans. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18028383.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Erdreich-Epstein A, Monforte HL, Lavey RS, Joshi S, Phillips JD, Villablanca JG: Successful multimodality therapy of recurrent multifocal juvenile granulosa cell tumor of the ovary. J Pediatr Hematol Oncol; 2002 Mar-Apr;24(3):229-33
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful multimodality therapy of recurrent multifocal juvenile granulosa cell tumor of the ovary.
  • Juvenile granulosa cell tumor (JGCT) of the ovary, a rare pediatric cancer, carries a very poor prognosis in advanced and recurrent cases.
  • She underwent surgery, chemotherapy (cisplatin/paclitaxel alternating with cisplatin/cyclophosphamide/etoposide/bleomycin), myeloablative chemotherapy (carboplatin/etoposide/melphalan) with autologous bone marrow transplant, and pelvic radiation.
  • She tolerated therapy well and is in complete remission 69 months after her recurrence.
  • [MeSH-major] Granulosa Cell Tumor / therapy. Neoplasm Recurrence, Local / therapy. Ovarian Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Transplantation. Child. Combined Modality Therapy. Disease-Free Survival. Female. General Surgery. Humans. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11990313.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 15
  •  go-up   go-down


11. Chudecka-Głaz A, Rzepka-Górska I, Błogowska A, Zielińska D: [Granulosa cell tumor in different periods of women's life]. Ginekol Pol; 2003 Sep;74(9):689-94
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Granulosa cell tumor in different periods of women's life].
  • Ovarian granulosa cell tumor is uncommon malignancies.
  • By virtue of histopathological examination we distinguish two subtype of GCT: adult type granulosa cell tumor typically in older women and juvenile granulosa cell tumor recognized primarily in children and young adults.
  • Depending on histological type patients suffer recurrences in different time after treatment, even many years from diagnosis.
  • OBJECTIVES: The aim of our study is clinical analysis of patients with AGCT and JGCT, especially the problem of choice of treatment, time to occurring recurrences and new possibility in long term follow up.
  • RESULTS: Among analyzed 22 patients 18 had adult type of granulosa cell tumor, mean age of these women was 47 years (32-72).
  • Juvenile type of granulosa cell tumor were recognized in 4 patients and they were from 4 to 7 years old.
  • In histopathological examination of 4 years old girl atypia and a lot of mitosis was observed and she was treated with chemotherapy.
  • Remained 3 girls live without evidence of disease and the longest time of follow up is 36 years.
  • 16 patients were treated with radiotherapy as an adjuvant treatment, two additionally with GnRH analogues.
  • Mean time to recurrence from diagnosis were 11.7 years.
  • Despite of aggressive chemotherapy four of these patients died during one year.
  • Remained 13 women with adult granulosa cell tumours live without evidence of disease and the longest time of observation is 9 years.
  • During long time follow up our patients were performed second-look laparoscopies, tested of estradiol levels and 5 of them also inhibin B levels which always correlated with actual condition.
  • CONCLUSION: Granulosa cell tumor is ovarian neoplasm of different behaviour.
  • [MeSH-major] Granulosa Cell Tumor / pathology. Granulosa Cell Tumor / surgery. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Child. Child, Preschool. Enzyme-Linked Immunosorbent Assay. Female. Humans. Hysterectomy. Inhibins / blood. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Poland. Recurrence. Survival Analysis. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14674109.001).
  • [ISSN] 0017-0011
  • [Journal-full-title] Ginekologia polska
  • [ISO-abbreviation] Ginekol. Pol.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 57285-09-3 / Inhibins
  •  go-up   go-down


12. Fleming NA, de Nanassy J, Lawrence S, Black AY: Juvenile granulosa and theca cell tumor of the ovary as a rare cause of precocious puberty: case report and review of literature. J Pediatr Adolesc Gynecol; 2010 Aug;23(4):e127-31
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Juvenile granulosa and theca cell tumor of the ovary as a rare cause of precocious puberty: case report and review of literature.
  • This case documents a rare cause of peripheral precocious puberty--a juvenile granulosa and theca cell ovarian tumor--and a brief review of the literature for this tumor type.
  • Pathology reported a juvenile granulosa and theca cell tumor of the ovary, FIGO stage 1A.
  • A literature review found that early stage disease has an excellent prognosis and that adjuvant chemotherapy is not indicated in this setting.
  • SUMMARY AND CONCLUSION: Juvenile granulosa and theca cell tumor of the ovary is a rare cause of peripheral precocious puberty, even more so than juvenile granulosa cell tumor, due to the theca component.
  • Treatment is surgical and an excellent prognosis is possible for early stage disease.
  • [MeSH-major] Granulosa Cell Tumor / complications. Ovarian Neoplasms / complications. Puberty, Precocious / etiology. Thecoma / complications

  • Genetic Alliance. consumer health - Precocious puberty.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 North American Society for Pediatric and Adolescent Gynecology. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20371195.001).
  • [ISSN] 1873-4332
  • [Journal-full-title] Journal of pediatric and adolescent gynecology
  • [ISO-abbreviation] J Pediatr Adolesc Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


13. Schneider DT, Calaminus G, Wessalowski R, Pathmanathan R, Harms D, Göbel U: Therapy of advanced ovarian juvenile granulosa cell tumors. Klin Padiatr; 2002 Jul-Aug;214(4):173-8
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy of advanced ovarian juvenile granulosa cell tumors.
  • BACKGROUND: Gonadal sex cord-stromal tumors are rare tumors that develop from the gonadal non-germ cell component such as granulosa, Sertoli or Leydig cells.
  • Among these, juvenile granulosa cell tumors (JGCT) constitute the largest subgroup of ovarian sex cord-stromal tumors during childhood and adolescence.
  • In local disease (FIGO stage I), the beneficial role of tumor-ovarectomy is well established.
  • In contrast, life expectancy in patients with advanced JGCT (FIGO stage >/= II) is short even after complete tumor resection.
  • The current literature provides only limited and inconclusive data regarding the value of adjuvant chemotherapy in such patients with advanced disease.
  • PATIENTS AND METHODS: Therefore, we analyzed the patients with FIGO stage >/= II JGCT who were prospectively documented as follow-up patients of the German MAKEI trials for non-testicular germ cell tumors and received the recommended cisplatin-based chemotherapy in an adjuvant setting.
  • Two patients received laparoscopic tumor resection, which was incomplete in both.
  • All patients received 4 or 6 cycles of adjuvant cisplatin-based three-agent chemotherapy in analogy to the current therapeutic concept applied in malignant germ cell tumors.
  • One patient with a large tumor and multiple peritoneal metastases additionally received 40 Gy abdominal irradiation.
  • RESULTS: All patients achieved complete clinical remission after initial surgery and adjuvant chemotherapy.
  • One patient developed a metachronous tumor of the contralateral ovary after 126 months follow-up and is still alive but currently in therapy of another recurrence.
  • Another patient suffered a tumor recurrence after 12 months but achieved a second complete remission with cisplatin chemotherapy after a follow-up of currently 4 months.
  • One patient achieved complete clinical remission but suffered a diffuse peritoneal tumor recurrence with massive ascites and finally died as a result of tumor progression.
  • In summary, at the time of this report 6 of 7 patients are alive after a median of 47 (15 - 138) months.
  • CONCLUSION: This analysis clearly demonstrates that advanced JGCT can be successfully treated with surgery followed by adjuvant cisplatin-based chemotherapy.
  • Therefore, this study reveals encouraging therapeutic perspectives in these otherwise fatal tumors that merit further investigation in a prospective cooperative trial.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Granulosa Cell Tumor / drug therapy. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant. Child. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy. Female. Follow-Up Studies. Germany. Humans. Neoplasm Staging. Prospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12165898.001).
  • [ISSN] 0300-8630
  • [Journal-full-title] Klinische Pädiatrie
  • [ISO-abbreviation] Klin Padiatr
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin
  •  go-up   go-down


14. Nossov VB, Schwartz PE, Tavassoli F: Markers of recurrence and predictors of clinical behavior of granulosa cell ovarian tumors. J Clin Oncol; 2004 Jul 15;22(14_suppl):5114

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Markers of recurrence and predictors of clinical behavior of granulosa cell ovarian tumors.
  • : 5114 Background: Granulosa cell tumors are rare ovarian cancers that can be associated with significant morbidity and mortality.
  • Little is known about prognostic markers of these tumors.
  • We attempted to identify some of the molecular markers that can be used to determine candidates for postoperative chemotherapy to prevent recurrence.
  • METHODS: 33 cases were retrieved from the files of Yale Tumor Registry over a period of 12 years from 1992 to 2003.
  • The patients ranged from 6 to 84 years of age, with a median age of 51 years.
  • Conventional prognostic factors (age, tumor size, mitotic activity, capsular invasion and histologic pattern) were assessed.
  • Morphological assessment identified 3 juvenile type, and 30 adult type tumors.
  • A few novel markers were evaluated in the tumors with and without recurrence as well as in the recurrent and metastatic tumors.
  • The histological and morphological characteristics of the granulosa cell tumors with and without recurrence and/or metastasis were correlated with the immunohistochemical findings for possible association between the expression of a specific tumor immunoprofile or marker expression and tumor behavior.
  • RESULTS: Positive inhibin staining was obtained only in adult type of GCT, almost exclusively in the primary site, and correlated with more advanced age (>47 y.o.).
  • We did not find a correlation between inhibin expression and tumor size.
  • CONCLUSIONS: Current data suggests that inhibin could be a predictor for favorable tumor behavior.
  • Testing tumor samples for cERB B4, cylin D2, EGFR may help to establish a stronger correlation between the presence of certain markers and tumor recurrence.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015683.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Till H, Schmidt H: Juvenile granulosa cell tumour (JGCT) of the ovary in a 6-year-old girl: laparoscopic resection achieves long-term oncological success. Eur J Pediatr Surg; 2005 Aug;15(4):292-4
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Juvenile granulosa cell tumour (JGCT) of the ovary in a 6-year-old girl: laparoscopic resection achieves long-term oncological success.
  • Juvenile granulosa cell tumours (JGCT) represent a rare malignancy in childhood and their laparoscopic resection has not been advocated yet.
  • We report on a 6-year-old girl with signs of precocious pseudo-puberty and an abdominal tumour.
  • Work-up revealed premature thelarche, vaginal discharge, elevated estrogen levels, and a solid tumour in the lower pelvis (6 x 4 x 3 cm in MRI).
  • The girl underwent laparoscopy (3 ports, 5-mm instruments), during which a non-invasive, mobile tumour of the left ovary was found.
  • Histopathology revealed a JGCT with an intact capsule (FIGO 1 a) which required no further chemotherapy.
  • Within 3 months postoperatively the girl's signs of precocious puberty had resolved and at present, after a follow-up of more than 3 years, there is no evidence of tumour recurrence.
  • Minimally invasive surgery of solid ovarian tumours in children remains controversial.
  • [MeSH-major] Granulosa Cell Tumor / surgery. Laparoscopy. Ovarian Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16163598.001).
  • [ISSN] 0939-7248
  • [Journal-full-title] European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift für Kinderchirurgie
  • [ISO-abbreviation] Eur J Pediatr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


16. Huang H, Huang R, Pan L: [High-dose chemotherapy with peripheral-blood stem cells transplantation in patients with advanced gynecological malignant tumors]. Zhonghua Fu Chan Ke Za Zhi; 2000 Aug;35(8):486-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [High-dose chemotherapy with peripheral-blood stem cells transplantation in patients with advanced gynecological malignant tumors].
  • OBJECTIVE: To evaluate the clinical effectiveness of high dose chemotherapy(HDC) with peripheral-blood stem cells transplantation(PBSCT) in the patients with advanced malignant tumors.
  • METHODS: Four patients with advanced or refractory ovarian carcinoma and 1 patient with recurrent fallopian tube carcinoma received the HDC with PBSCT after optimal tumor debulking.
  • Of whom 4 patients were with the recurrent or progressive tumors, 1 patient received HDC as primary chemotherapy.
  • The response and toxicity were assessed after treatment.
  • One case died from the recurrence of juvenile granulosa cell tumor.
  • The tumors were all recurrent among the 4 survival patients.
  • The average periods of recurrence after HDC treatment was 9 months.
  • The median time to recover a neutrophil count greater than 0.5 x 10(9)/L was 14 days and a platelet count greater than 50 x 10(9)/L was 17 days.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Ovarian Neoplasms / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11776205.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


17. Merras-Salmio L, Vettenranta K, Möttönen M, Heikinheimo M: Ovarian granulosa cell tumors in childhood. Pediatr Hematol Oncol; 2002 Apr-May;19(3):145-56
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian granulosa cell tumors in childhood.
  • Granulosa cell tumors (GCT) of the ovary are prepubertal in 5% of the patients.
  • These juvenile granulosa cell tumors (JGCTs) are usually benign.
  • GCTs belong to ovarian sex cord-stromal tumors, the more common ovarian tumors being epidermal and germinal.
  • However, more widely spread tumors are difficult to treat and cause mortality.
  • Cisplatin-containing chemotherapy can induce remissions in adult GCTs.
  • The authors describe 3 children with GCT and review current data on this rare tumor from molecular biology to clinical aspects.
  • [MeSH-major] Granulosa Cell Tumor / diagnosis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Child. Child, Preschool. Female. Humans. Infant. Prognosis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11936727.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 49
  •  go-up   go-down


18. Grabiec M, Kwiatkowski M, Walentowicz M, Greźlikowska U: [Current views on treatment of the ovarian granulosa-cell tumor]. Ginekol Pol; 2008 Jan;79(1):42-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Current views on treatment of the ovarian granulosa-cell tumor].
  • The granulosa-cell tumor (folliculoma) is a rare type of ovarian neoplasm, accounting for 5% of all cases.
  • It is the most common type of sex cord-stromal tumors, diagnosed in 70% of cases.
  • The granulosa-cell tumor is a hormone active one, originating from granulosa cells which produce estradiol.
  • Overproduction of estradiol is helpful in the diagnosis of the tumor because of its numerous symptoms.
  • There are two types of folliculoma: juvenile (5%) and adult (95%).
  • The juvenile type is mostly recognized (90%) in FIGO I stage and has a better prognosis.
  • Operation is often a sufficient way of treatment in this group.
  • Tumors in higher stages are more aggressive and must be treated further.
  • Patients with the disease diagnosed in higher stages must be treated by adjuvant radiotherapy or chemotherapy.
  • Recurrence appears often many years after the treatment and has high mortality.
  • Many old (platinum) and new (taxans) agents are active when used in treatment of this type of tumor.
  • Randomized study must be made to establish standard therapy of granulosa-cell tumor.
  • Currently, the most frequent way of treatment is chemotherapy with BEP (Blemycyna, Etopozyd, Cisplatyna).
  • [MeSH-major] Granulosa Cell Tumor / pathology. Granulosa Cell Tumor / therapy. Ovarian Neoplasms / pathology. Ovarian Neoplasms / therapy
  • [MeSH-minor] Adult. Age Factors. Aged. Female. Humans. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / therapy. Neoplasm Staging. Prognosis. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18510049.001).
  • [ISSN] 0017-0011
  • [Journal-full-title] Ginekologia polska
  • [ISO-abbreviation] Ginekol. Pol.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 21
  •  go-up   go-down


19. Loeffen JL, Wijnen M, Schijf CP, van Wieringen P: [Ovarian tumour in a girl with chronic abdominal pain and distension]. Ned Tijdschr Geneeskd; 2006 Mar 25;150(12):677-80
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ovarian tumour in a girl with chronic abdominal pain and distension].
  • [Transliterated title] Ovariumtumor bij een meisje met chronische buikpijn en zwelling van de buik.
  • The cause was a Sertoli-Leydig cell tumour originating in the left ovary.
  • Ovarian tumours are rarely seen in children.
  • The sex cordstromal tumours constitute a heterogeneous subgroup.
  • Two of the most frequently observed sex cord-stromal tumours are the juvenile granulosa cell tumour and the Sertoli-Leydig cell tumour.
  • Even though these tumours may contain histologically malignant characteristics, their behaviour is usually benign.
  • In addition, pressure from the tumour mass may result in symptoms in adjacent organ systems.
  • Patients with advanced disease may benefit from adjuvant chemotherapy.
  • Chronic abdominal pain is frequently observed in children and, in some rare cases, may be caused by ovarian tumours.
  • [MeSH-major] Ovarian Neoplasms / diagnosis. Sertoli Cell Tumor / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16613252.001).
  • [ISSN] 0028-2162
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


20. Oltmann SC, Fischer A, Barber R, Huang R, Hicks B, Garcia N: Pediatric ovarian malignancy presenting as ovarian torsion: incidence and relevance. J Pediatr Surg; 2010 Jan;45(1):135-9
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumors with neoplastic pathology (malignant and benign) were analyzed and compared with all reported cases in the literature.
  • Malignancies consisted of serous borderline tumors (2), juvenile granulosa cell tumor (1), and dysgerminoma (1).
  • All were stage I: the former were stage IA and cured with resection alone, and 1 was a stage IB dysgerminoma, which required chemotherapy.
  • The malignancies were juvenile granulosa cell tumor (n = 4), dysgerminoma (n = 2), serous borderline tumors (n = 2), and 1 undifferentiated adenocarcinoma.
  • Further study is needed to determine if delaying resection by weeks in those cases of persistent masses would result in tumor progression and thus change prognosis.
  • [MeSH-major] Ovarian Diseases / diagnosis. Ovarian Neoplasms / diagnosis. Torsion Abnormality / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / surgery. Adolescent. Adult. Age Factors. Child. Child, Preschool. Diagnosis, Differential. Dysgerminoma / diagnosis. Dysgerminoma / surgery. Female. Granulosa Cell Tumor / diagnosis. Granulosa Cell Tumor / surgery. Humans. Incidence. Infant

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20105593.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 20
  •  go-up   go-down


21. Mehta H, Trivedi P, Parikh B, Shukla K, Shah MJ: Clinicopathological prognostic factors of adult granulosa cell tumor of the ovary--a study of 37 cases. Indian J Pathol Microbiol; 2005 Oct;48(4):439-43
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological prognostic factors of adult granulosa cell tumor of the ovary--a study of 37 cases.
  • Adult granulosa cell tumor (GCT) of the ovary is the most common malignancy amongst the sex cord stromal tumors.
  • Clinical stage, age, tumor size, residual disease and several histologic factors have been reported to be of prognostic significance.
  • Out of 54 granulosa cell tumors, 40 cases were evaluable which includes 37 cases of adult GCT and 3 cases of juvenile GCT.
  • All patients were treated surgically and 62.1% of adult GCTs were given post-operative chemotherapy.
  • Clinical stage, presence of residual disease and tumor volume were the most important prognostic factors.
  • Age of patient, menstrual status, post-operative chemotherapy, mitosis or histological patterns were of little significance in our study.
  • [MeSH-major] Granulosa Cell Tumor / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. India / epidemiology. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16366090.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


22. Geetha P, Nair MK: Granulosa cell tumours of the ovary. Aust N Z J Obstet Gynaecol; 2010 Jun;50(3):216-20
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulosa cell tumours of the ovary.
  • Granulosa cell tumours are rare, potentially malignant sex cord stromal tumours of the ovary.
  • As a result, most of them will be in an early stage at the time of initial diagnosis.
  • The tumour can manifest in young girls as a juvenile form and conservative management with unilateral salpingo-opherectomy may be an option in them as 95% are unilateral.
  • Surgery is the treatment of choice and initial staging laparatomy a determinant recurrence.
  • Advance stage of the tumour, its size (>5 cm), mitotic figures (>10/hpf), nuclear atypia and absence of call-exner bodies are poor prognostic factors.
  • Such tumours are characterised by late recurrences and this necessitates a prolonged follow-up.
  • Tumour markers such as inhibin and estradiol are useful in follow-up.
  • Chemotherapy, radiotherapy and hormone replacement therapy have very little role in the initial treatment and may be suggested in case of recurrences.
  • With appropriate treatment, a better survival rate can be achieved as against other ovarian malignancies.
  • [MeSH-major] Granulosa Cell Tumor / diagnosis. Granulosa Cell Tumor / therapy. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20618236.001).
  • [ISSN] 1479-828X
  • [Journal-full-title] The Australian & New Zealand journal of obstetrics & gynaecology
  • [ISO-abbreviation] Aust N Z J Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


23. Kalfa N, Philibert P, Patte C, Ecochard A, Duvillard P, Baldet P, Jaubert F, Fellous M, Sultan C: Extinction of FOXL2 expression in aggressive ovarian granulosa cell tumors in children. Fertil Steril; 2007 Apr;87(4):896-901
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extinction of FOXL2 expression in aggressive ovarian granulosa cell tumors in children.
  • OBJECTIVE: In the female gonad, FOXL2 is a key factor for proper differentiation of granulosa cells (GC) during folliculogenesis and its expression persists in the ovary after birth.
  • The aim of this multicentric nationwide study was to determine whether FOXL2 expression varies during tumoral proliferation of GC cells in juvenile ovarian GC tumors (OGCT).
  • PATIENT(S): Between 1994 and 2004, 26 patients with juvenile OGCT were reported in the TGM95 database of the French Society for Childhood Cancer (SFCE) and from eight pediatric endocrinology centers.
  • MAIN OUTCOME MEASURE(S): Level of FOXL2 expression within the tumor, International Federation of Gynecology and Obstetrics classification, and tumor recurrences.
  • Patients with no or reduced expression of FOXL2 more frequently exhibited associated hemorrhagic ascites, higher mitotic activity in the tumor, and significantly more advanced oncologic staging.
  • All patients requiring complementary treatment (n = 7; chemotherapy or complementary surgery) had reduced expression of FOXL2 in the tumor.
  • CONCLUSION(S): These results show that FOXL2 is not expressed or is underexpressed in juvenile OGCT with an aggressive pattern of progression, and it thus may be a prognostic factor for these tumors.
  • [MeSH-major] Forkhead Transcription Factors / analysis. Granulosa Cell Tumor / chemistry. Ovarian Neoplasms / chemistry
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Granulosa Cells / pathology. Humans. Immunohistochemistry. Infant. Neoplasm Staging. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17430735.001).
  • [ISSN] 1556-5653
  • [Journal-full-title] Fertility and sterility
  • [ISO-abbreviation] Fertil. Steril.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / FOXL2 protein, human; 0 / FOXO1 protein, human; 0 / Forkhead Transcription Factors
  •  go-up   go-down


24. Leibl S, Bodo K, Gogg-Kammerer M, Hrzenjak A, Petru E, Winter R, Denk H, Moinfar F: Ovarian granulosa cell tumors frequently express EGFR (Her-1), Her-3, and Her-4: An immunohistochemical study. Gynecol Oncol; 2006 Apr;101(1):18-23
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian granulosa cell tumors frequently express EGFR (Her-1), Her-3, and Her-4: An immunohistochemical study.
  • OBJECTIVE: Up to 50% of patients with ovarian granulosa cell tumors (GCTs) will develop recurrences; some of these recurrences can be seen as late as 30 years following the initial surgical treatment.
  • Combined chemotherapy and radiotherapy are currently used for patients with advanced or recurrent disease.
  • The aim of this study was to investigate the possible eligibility of patients with GCTs for anti-Her therapy.
  • METHODS: The immunohistochemical expression of EGFR (Her-1), Her-2, Her-3, and Her-4 was analyzed in a group of ovarian GCTs encompassing 38 adult type and 2 juvenile type.
  • Eight tumors (20%) were exclusively positive for EGFR (Her-1).
  • Positive reactions for Her-3 and Her-4 were observed in 18 (45%) and 23 (57.5%) tumors.
  • Four tumors (10%) showed positivity for Her-3 and Her-4 but were negative for EGFR (HER-1).
  • These findings provide some evidence to further explore the potential use of agents targeting these receptors (particularly EGFR) in the treatment of ovarian GCTs.
  • [MeSH-major] Granulosa Cell Tumor / metabolism. Ovarian Neoplasms / metabolism. Receptor, Epidermal Growth Factor / biosynthesis. Receptor, ErbB-3 / biosynthesis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16330088.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / ERBB4 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-3; EC 2.7.10.1 / Receptor, ErbB-4
  •  go-up   go-down


25. Schneider DT, Jänig U, Calaminus G, Göbel U, Harms D: Ovarian sex cord-stromal tumors--a clinicopathological study of 72 cases from the Kiel Pediatric Tumor Registry. Virchows Arch; 2003 Oct;443(4):549-60
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian sex cord-stromal tumors--a clinicopathological study of 72 cases from the Kiel Pediatric Tumor Registry.
  • We analyzed 72 patients with ovarian sex cord-stromal tumors (OSCST) registered at the German Pediatric Tumor Registry in Kiel over a 20-year period.
  • Juvenile granulosa cell tumors (JGCT, n=48) were the most frequent histological subtype.
  • In addition, there were 14 Sertoli-Leydig cell tumors, 5 sclerosing stromal tumors, 2 sex cord tumors with annular tubules, 2 thecomas and 1 steroid cell tumor.
  • Compared with adult granulosa cell tumors, JGCT showed pronounced mitotic activity [mean 9.8 mitoses/10 high power field (HPF)], which was significantly higher than in other histological subtypes (2.7/10 HPF, P=0.001).
  • Immunohistochemical analysis revealed frequent coexpression of vimentin (positive in 52/52 examined tumors), cytokeratin (27/33), and inhibin (19/20).
  • Of patients, 12 with Ic or higher stage tumors received adjuvant cisplatinum-based chemotherapy.
  • In conclusion, this analysis confirms that the majority of patients with OSCST present at low tumor stage and that prognosis in these patients is excellent.
  • Refractory tumors are characterized by high proliferative activity.
  • Therefore, histopathological evaluation substantially contributes to risk assessment in patients with OSCST and might be useful for therapy stratification in prospective therapeutic protocols.
  • [MeSH-major] Ovarian Neoplasms / pathology. Sex Cord-Gonadal Stromal Tumors / pathology
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Infant. Sertoli-Leydig Cell Tumor / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1985 Aug;9(8):543-69 [3911780.001]
  • [Cites] Scand J Gastroenterol Suppl. 1999;230:64-70 [10499464.001]
  • [Cites] Gynecol Oncol. 1997 Feb;64(2):282-4 [9038278.001]
  • [Cites] Obstet Gynecol Surv. 1998 Apr;53(4):240-7 [9560834.001]
  • [Cites] Gynecol Oncol. 1997 Jun;65(3):447-52 [9190974.001]
  • [Cites] Am J Obstet Gynecol. 1997 Dec;177(6):1450-7 [9423750.001]
  • [Cites] Acta Obstet Gynecol Scand. 2001 Nov;80(11):1069-74 [11703210.001]
  • [Cites] Tumori. 2001 Jan-Feb;87(1):47-53 [11669558.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Sep;86(9):4041-6 [11549623.001]
  • [Cites] Cancer. 1997 May 15;79(10):1951-5 [9149022.001]
  • [Cites] Am J Surg Pathol. 1984 Aug;8(8):575-96 [6465418.001]
  • [Cites] J Pathol. 1987 Aug;152(4):253-63 [2444685.001]
  • [Cites] Am J Surg Pathol. 1985 Oct;9(10):737-43 [4061731.001]
  • [Cites] Obstet Gynecol. 1996 Apr;87(4):527-31 [8602303.001]
  • [Cites] Int J Gynaecol Obstet. 2000 Aug;70(2):209-62 [11041682.001]
  • [Cites] Int J Gynecol Pathol. 1998 Jan;17 (1):46-53 [9475192.001]
  • [Cites] Pediatr Pathol. 1993 Jul-Aug;13(4):389-400 [8372023.001]
  • [Cites] Gynecol Oncol. 1993 Jan;48(1):119-23 [8423014.001]
  • [Cites] Virchows Arch. 1997 Apr;430(4):301-9 [9134041.001]
  • [Cites] Anticancer Drugs. 1998 Aug;9(7):621-3 [9773806.001]
  • [Cites] Gynecol Oncol. 1995 Jun;57(3):417-22 [7774848.001]
  • [Cites] Eur J Cell Biol. 1985 May;37:175-90 [3896804.001]
  • [Cites] Virchows Arch. 1996 Feb;427(5):497-502 [8624579.001]
  • [Cites] Gynecol Oncol. 2001 Apr;81(1):113-6 [11277661.001]
  • [Cites] Mod Pathol. 1997 Nov;10(11):1101-5 [9388060.001]
  • [Cites] Klin Padiatr. 2002 Jul-Aug;214(4):173-8 [12165898.001]
  • [Cites] Arch Fr Pediatr. 1992 Nov;49(9):793-8 [1300967.001]
  • [Cites] J Clin Oncol. 1988 Jun;6(6):990-5 [3373268.001]
  • (PMID = 12910419.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


26. Schneider DT, Calaminus G, Harms D, Göbel U, German Maligne Keimzelltumoren Study Group: Ovarian sex cord-stromal tumors in children and adolescents. J Reprod Med; 2005 Jun;50(6):439-46
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian sex cord-stromal tumors in children and adolescents.
  • Ovarian sex cord-stromal tumors (OSCSTs) are a heterogeneous group of tumors that develop from the gonadal non-germ-cell component.
  • Despite recent advances in the clinical and histopathologic diagnosis of OSCSTs, a high degree of uncertainty remains with regard to adequate therapy, particularly in patients presenting with microscopic or macroscopic tumor spread.
  • In addition, we summarize the data from our clinical, histopathologic and genetic analyses of patients that were prospectively reported to the German MAKEI protocols for treatment of nontesticular malignant germ cell tumors.
  • Among these patients, juvenile granulosa cell tumors (JGCTs) constitute the most frequent histologic subtype, followed by Sertoli-Leydig cell tumors (SLCTs) and sclerosing stromal tumors.
  • Patients with JGCT and SLCT show greater mitotic activity than do all those with other histologic types.
  • In addition, prognosis correlates with tumor stage according to the International Federation of Obstetrics and Gynecology.
  • Nevertheless, we observed a favorable response to cisplatin-based chemotherapy in the majority of stage II and III tumors.
  • Genetic analysis of 27 tumors available for comparative genomic hybridization analysis revealed normal profiles in the majority of tumors and whole chromosomal gain, such as a gain of 12 in single tumors, with no consistent pattern with regard to histology or clinical outcome.
  • This analysis confirmed that most OSCSTs present at a low tumor stage and that prognosis in these patients is excellent.
  • Most important, patients at high risk can be identified through clinical and histopathologic analysis, and the majority can be treated successfully with adjuvant cisplatinum-based chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / therapy. Sex Cord-Gonadal Stromal Tumors / therapy
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant. Child. Cisplatin / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Female. Germany. Humans. Neoplasm Staging. Prognosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16050568.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin
  • [Number-of-references] 27
  •  go-up   go-down


27. Cass DL, Hawkins E, Brandt ML, Chintagumpala M, Bloss RS, Milewicz AL, Minifee PK, Wesson DE, Nuchtern JG: Surgery for ovarian masses in infants, children, and adolescents: 102 consecutive patients treated in a 15-year period. J Pediatr Surg; 2001 May;36(5):693-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of those presenting with acute abdominal pain (n = 59), 25 (42%) had ovarian torsion (14 associated with a mature teratoma), and only 1 (2%) had a malignant tumor.
  • There was no age difference between those with benign disease (9.9 +/- 5.6 years; n = 96) and those with malignant tumors (8.6 +/- 3.9 years, n = 10).
  • Nine children had 10 operations for presumed malignant tumors (3 dysgerminomas, 2 immature teratomas with foci of yolk sac tumor, 2 juvenile granulosa cell tumors, 1 yolk sac tumor, and 1 Sertoli-Leydig cell tumor).
  • These patients all had unilateral salpingo-oophorectomy, 4 had chemotherapy, and all are now disease free at 8.4 +/- 4.1 years follow-up.
  • [MeSH-minor] Abdominal Pain / etiology. Adolescent. Adult. Age Distribution. Age Factors. Age of Onset. Biopsy. Child. Child, Preschool. Diagnosis, Differential. Disease-Free Survival. Fallopian Tubes / surgery. Female. Follow-Up Studies. Hospitals, Pediatric. Humans. Infant. Infant, Newborn. Omentum / surgery. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 by W.B. Saunders Company.
  • (PMID = 11329568.001).
  • [ISSN] 0022-3468
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Cecchetto G, Alaggio R, Bisogno G, Virgone C, Dall'Igna P, Terenziani M, Boldrini R, D'Onofrio V, Ferrari A, Bernini G: Sex cord-stromal tumors of the testis in children. A clinicopathologic report from the Italian TREP project. J Pediatr Surg; 2010 Sep;45(9):1868-73
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sex cord-stromal tumors of the testis in children. A clinicopathologic report from the Italian TREP project.
  • PURPOSE: Testicular sex cord-stromal tumors (SCSTs) are very rare in children and include a variety of neoplasms with different clinical features and biologic behavior.
  • Aim of the study was to report the clinical findings and results observed in a series of patients with testicular SCST, registered in a multi-institutional Italian network on rare tumors in children and adolescents.
  • Chemotherapy was recommended in patients with incomplete surgery or metastatic disease.
  • All patients underwent primary removal of the tumor; orchiectomy with high ligation of spermatic cord was performed in 7 and tumor enucleation in 4.
  • At histology, 4 patients had Leydig cell tumors, 4 juvenile granulosa cell tumors, 1 Sertoli cell tumor, 1 incompletely differentiated SCST, and 1 SCST with an intermediate pattern Sertoli cell tumor/mixed form.
  • [MeSH-major] Sex Cord-Gonadal Stromal Tumors / pathology. Testicular Neoplasms / pathology
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Humans. Infant. Italy. Male. Orchiectomy. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20850634.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down






Advertisement